Kingfa science & technology (India) Limited has announced the commencement of commercial production at its newly established manufacturing unit in Bhiwadi, Rajasthan. The company informed stock exchanges about this significant operational milestone through a regulatory filing dated February 23, 2026.

Facility Details and Location

The new manufacturing unit is strategically positioned in Rajasthan's industrial corridor. Key facility parameters include:

Regulatory Compliance and Disclosure

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure aligns with Para B of Part A of Schedule III to the said Regulations and follows the company's Policy for Determination of Materiality of Events and Information.

Company Secretary and Compliance Officer Deepak Vyas signed the regulatory filing, ensuring proper compliance with stock exchange notification requirements. The communication was simultaneously sent to both major Indian stock exchanges - the National Stock Exchange of India Limited and BSE Limited.

Strategic Significance

The commencement of commercial production at the Bhiwadi facility represents a significant expansion in Kingfa Science & Technology's manufacturing capabilities. The facility's location in RIICO Industrial Area provides access to established industrial infrastructure and connectivity advantages.

This operational milestone demonstrates the company's commitment to expanding its manufacturing footprint in India and enhancing production capacity to meet market demands.

Kingfa Science & Technology (India) Limited has filed its monitoring agency report for the quarter ended December 31, 2025, detailing the utilization of proceeds from its Rs.500 crore preferential issue. The report, prepared by CARE Ratings Limited as the monitoring agency, was submitted to both NSE and BSE on February 09, 2026.

Issue Proceeds Utilization Overview

During Q3FY26, the company utilized Rs.115.15 crore from the total preferential issue proceeds of Rs.500 crore. The monitoring agency confirmed that all utilization aligned with the disclosures in the offer document, with no deviations reported.

Object-wise Progress Status

The preferential issue proceeds were allocated across five specific objects, with completion targeted by June 2027. The current utilization status shows progress in two key areas:

Deployment of Unutilized Funds

The company has deployed the remaining Rs.384.85 crore in fixed deposits with Industrial and Commercial Bank of China Limited, generating attractive returns. The deployment strategy ensures capital preservation while earning steady income:

General Corporate Purpose Breakdown

The Rs.54.86 crore utilized for general corporate purposes was distributed across operational requirements:

• Vendor Payments: Rs.39.19 crore for operational expenses
• Consulting Fees: Rs.15.66 crore for securities allotment services
• Bank Charges: Rs.0.01 crore for banking services

Regulatory Compliance and Monitoring

CARE Ratings Limited, serving as the monitoring agency under Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirmed no material deviations from the offer document. The report was reviewed by the company's Audit Committee and Board of Directors before submission to stock exchanges. All government and statutory approvals related to the objects will be obtained as and when required, with no unfavorable events affecting the viability of the stated objects reported during the quarter.